Your browser doesn't support javascript.
loading
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.
Wang, Kang; Yu, Hong-Ming; Xiang, Yan-Jun; Cheng, Yu-Qiang; Ni, Qian-Zhi; Guo, Wei-Xing; Shi, Jie; Feng, Shuang; Zhai, Jian; Cheng, Shu-Qun.
Afiliação
  • Wang K; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Yu HM; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Xiang YJ; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Cheng YQ; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Ni QZ; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Guo WX; CAS Key Laboratory of Nutrition, Metabolism & Food Safety, Shanghai Institute of Nutrition & Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
  • Shi J; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Feng S; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Zhai J; Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
  • Cheng SQ; Department II of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200433, China.
Future Oncol ; 19(15): 1029-1035, 2023 May.
Article em En | MEDLINE | ID: mdl-37132469
ABSTRACT
Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab. The primary end point is objective response rate; the secondary end points are overall survival, disease control rate, progression-free survival, time to progression, duration of response and safety. The results of this trial are expected to provide novel, safe and effective treatment options for patients with advanced BTC, which could further improve their prognosis. Clinical Trial Registration ChiCTR2100049830 (ChiCTR.org).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China